Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64


New Breast Cancer Radiotherapy Technology Confers Higher Complications and Costs Before Effectiveness Proven: A Medicare Data Analysis.

Gold HT, Walter D, Tousimis E, Hayes MK.

Inquiry. 2018 Jan-Dec;55:46958018759115. doi: 10.1177/0046958018759115.


Evaluating the efficacy of post-surgery adjuvant therapies used for ductal carcinoma in situ patients: a network meta-analysis.

Wang L, Xia Y, Liu D, Zeng Y, Chang L, Li L, Hou Y, Ge L, Li W, Liu Z.

Oncotarget. 2017 Apr 21;8(45):79257-79269. doi: 10.18632/oncotarget.17366. eCollection 2017 Oct 3.


Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ.

Shurell E, Olcese C, Patil S, McCormick B, Van Zee KJ, Pilewskie ML.

Cancer. 2018 Jan 1;124(1):46-54. doi: 10.1002/cncr.30972. Epub 2017 Sep 28.


The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden.

Sackey H, Hui M, Czene K, Verkooijen H, Edgren G, Frisell J, Hartman M.

Breast Cancer Res. 2016 Oct 18;18(1):105.


Balloon-based adjuvant radiotherapy in breast cancer: comparison between (99m)Tc and HDR (192)Ir.

de Campos TP, de Lima CF, Cuperschmid EM.

Radiol Bras. 2016 Mar-Apr;49(2):92-7. doi: 10.1590/0100-3984.2015.0010.


Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.

Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N.

Lancet. 2016 Feb 27;387(10021):857-65. doi: 10.1016/S0140-6736(15)01169-1. Epub 2015 Dec 11.


Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.

Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N.

Lancet. 2016 Feb 27;387(10021):849-56. doi: 10.1016/S0140-6736(15)01168-X. Epub 2015 Dec 11.


Radiotherapy in the management of early breast cancer.

Wang W.

J Med Radiat Sci. 2013 Mar;60(1):40-6. doi: 10.1002/jmrs.1. Epub 2013 Feb 3. Review.


Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years.

Subhedar P, Olcese C, Patil S, Morrow M, Van Zee KJ.

Ann Surg Oncol. 2015 Oct;22(10):3273-81. doi: 10.1245/s10434-015-4740-8. Epub 2015 Jul 28. Erratum in: Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1618.


Final results from a multicenter prospective study ( JROSG 05-5) on postoperative radiotherapy for patients with ductal carcinoma in situ with an involved surgical margin or close margin widths of 1 mm or less.

Shikama N, Sekiguchi K, Nakamura N, Sekine H, Nakayama Y, Imanaka K, Akiba T, Aoki M, Hatayama Y, Ogo E, Kagami Y, Kawashima M, Karasawa K.

J Radiat Res. 2015 Sep;56(5):830-4. doi: 10.1093/jrr/rrv034. Epub 2015 Jun 20.


Racial disparities in risk of second breast tumors after ductal carcinoma in situ.

Liu Y, Colditz GA, Gehlert S, Goodman M.

Breast Cancer Res Treat. 2014 Nov;148(1):163-73. doi: 10.1007/s10549-014-3151-z. Epub 2014 Sep 27.


Web based pathology assessment in RTOG 98-04.

Woodward WA, Sneige N, Winter K, Kuerer HM, Hudis C, Rakovitch E, Smith BL, Pierce LJ, Germano I, Pu AT, Walker EM, Grisell DL, White JR, McCormick B; Radiation Therapy Oncology Group (RTOG).

J Clin Pathol. 2014 Sep;67(9):777-80.


Intraoperative Electron Radiotherapy (IOERT) as an Alternative to Standard Whole Breast Irradiation: Only for Low-Risk Subgroups?

Maluta S, Dall'Oglio S, Goer DA, Marciai N.

Breast Care (Basel). 2014 May;9(2):102-6. doi: 10.1159/000362392. Review.


Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study.

Sprague BL, McLaughlin V, Hampton JM, Newcomb PA, Trentham-Dietz A.

Breast Cancer Res Treat. 2013 Aug;141(1):145-54. doi: 10.1007/s10549-013-2670-3. Epub 2013 Aug 25.


β1-Integrin via NF-κB signaling is essential for acquisition of invasiveness in a model of radiation treated in situ breast cancer.

Nam JM, Ahmed KM, Costes S, Zhang H, Onodera Y, Olshen AB, Hatanaka KC, Kinoshita R, Ishikawa M, Sabe H, Shirato H, Park CC.

Breast Cancer Res. 2013;15(4):R60.


Using therapeutic mammoplasty to extend the role of breast-conserving surgery in women with larger or ptotic breasts.

Currie A, Chong K, Davies GL.

Ann R Coll Surg Engl. 2013 Apr;95(3):192-5. doi: 10.1308/003588413X13511609958091.


GammaPod-a new device dedicated for stereotactic radiotherapy of breast cancer.

Yu CX, Shao X, Zhang J, Regine W, Zheng M, Yu YS, Deng J, Duan Z.

Med Phys. 2013 May;40(5):051703. doi: 10.1118/1.4798961.


Ductal carcinoma in situ of the breast: a surgical perspective.

Badruddoja M.

Int J Surg Oncol. 2012;2012:761364. doi: 10.1155/2012/761364. Epub 2012 Sep 4.


Ductal carcinoma in situ of the breast.

Lee RJ, Vallow LA, McLaughlin SA, Tzou KS, Hines SL, Peterson JL.

Int J Surg Oncol. 2012;2012:123549. doi: 10.1155/2012/123549. Epub 2012 Jul 18.


No excess mortality in patients aged 50 years and older who received treatment for ductal carcinoma in situ of the breast.

Bastiaannet E, van de Water W, Westendorp RG, Janssen-Heijnen ML, van de Velde CJ, de Craen AJ, Liefers GJ.

Int J Surg Oncol. 2012;2012:567506. doi: 10.1155/2012/567506. Epub 2012 May 13.

Supplemental Content

Support Center